Ghrelin, obesity and diabetes.

Published

Journal Article (Review)

The high prevalence of obesity and diabetes will lead to higher rates of morbidity and mortality. The search for drugs to treat these metabolic disorders has, therefore, intensified. The stomach-derived peptide ghrelin regulates food intake and body weight. Recent work suggests that ghrelin also controls glucose metabolism. In addition, current evidence suggests that most of the actions of ghrelin could contribute to the metabolic syndrome. The ghrelin signaling system is, therefore, a promising target for the development of new drugs for the treatment of obesity and diabetes. Agents that block the ghrelin signaling system might be especially useful targets. This Review summarizes the potential and the limitations of ghrelin as a tool to better understand, prevent and treat obesity and diabetes.

Full Text

Duke Authors

Cited Authors

  • Wiedmer, P; Nogueiras, R; Broglio, F; D'Alessio, D; Tschöp, MH

Published Date

  • October 2007

Published In

Volume / Issue

  • 3 / 10

Start / End Page

  • 705 - 712

PubMed ID

  • 17893689

Pubmed Central ID

  • 17893689

Electronic International Standard Serial Number (EISSN)

  • 1745-8374

Digital Object Identifier (DOI)

  • 10.1038/ncpendmet0625

Language

  • eng

Conference Location

  • England